Relative dose intensity of first-line triplet chemotherapy in metastatic colorectal cancer
Abstract
PURPOSE: Relative dose intensity (RDI) is a measurement of chemotherapy (CT) dose defined as the actual dose received divided by the standard calculated dose during a set period. The study objective was to assess the impact of a RDI ≥ 80% on response and survival of patients treated in first line CT by FOLFOXIRI or FOLFIRINOX ± Bevacizumab (BV) for an unresectable metastatic colorectal cancer (mCRC). MATERIALS AND METHODS: It was a retrospective, non-interventional, multicenter study calculating RDI from the first cycles of CT to the first CT-scan evaluation (CT-scan1). Objective response and disease control rates (ORR and DCR), progression-free survival (PFS) and overall survival (OS) were compared between patients with RDI ≥ 80% and <80% and results were adjusted for age, gender, ECOG, tumor location, number of metastatic sites, RAS and BRAF status, the CT regimen, the use of BV, the delay from C1 to CT scan1. RESULTS: Among 152 screened patients, 100 met inclusion criteria, with a mean (± standard deviation) age at 59.0 (± 10.7) years. The ECOG performance status was 0-1 in 96 (96%) patients; metastases were synchronous in 95 (95%), RAS and BRAF were mutated in 60 (60%) and 22 (22%), respectively. ORR was observed in 51 (51%) at CT-scan1 with median PFS and OS of 10.5 and 21.9 months, respectively. A RDI ≥ 80% was observed in 44 (44%) patients without impact on ORR (ORa: 1.04, 95% CI: 0.37 to 2.89, p = 0.94) but was significantly associated to improved PFS and OS with HRa 0.50 (95%CI: 0.29 to 0.87, p = 0.013) and 0.52 (95% CI: 0.29 to 0.91, p = 0.023), respectively. CONCLUSION: Our results suggest a low level of FOLFOXIRI or FOLFIRINOX +/- BV exposure in first-line mCRC is associated with a significant trend on PFS and OS.
Related
- Sotorasib plus panitumumab and 5-fluorouracil in first-line treatment of patients with unresectable KRAS G12C mutated colorectal cancer unfit for a doublet/triplet chemotherapy: ENGIC 01 – PRODIGE 107 – FFCD 2306 – COLOSOTO trial
- Relative dose intensity of gemcitabine-nab-paclitaxel combination as second-line or more in locally advanced or metastatic pancreatic adenocarcinoma
- Survival Outcomes in Metastatic Colorectal Cancer Patients with BRAF Mutations Undergoing Targeted Chemotherapy: A Reconstructed Individual Patient Data Meta-Analysis of Randomized Controlled Trials.
- [Comment] Tumor debulking in combination with chemotherapy in multiorgan metastatic colorectal cancer: the ORCHESTRA randomized clinical trial
- Geriatric Assessment-Based Stratification to Evaluate Treatment Intensity, Quality of Life, and Survival in Older Patients With Metastatic Colorectal Cancer: Protocol for a Prospective Observational Study.
BibTeX
@article{hoba2026relative,
title = {{Relative dose intensity of first-line triplet chemotherapy in metastatic colorectal cancer}},
author = {Julien Hoba and Adrien Grancher and Vincent Hautefeuille and Anthony Turpin and Karine Bouhier-Leporrier and Marie-Pierre Galais and Anne-Laure Bignon and Aude Di Fiore and Romain Desgrippes and Laurent Miglianico and Benoit Avisse and Mathieu Baconnier and You-Heng Lam and Marie Dutherage and David Sefrioui and Karine Le Malicot and Jean-Marc Phelip and Pierre Michel and André Gillibert and Frédéric Di Fiore},
journal = {Digestive and Liver Disease},
year = {2026},
month = sep,
doi = {10.1016/j.dld.2024.05.014},
url = {https://hal.science/hal-05742239v1},
note = {CC BY},
}
RIS
TY - JOUR
TI - Relative dose intensity of first-line triplet chemotherapy in metastatic colorectal cancer
AU - Julien Hoba
AU - Adrien Grancher
AU - Vincent Hautefeuille
AU - Anthony Turpin
AU - Karine Bouhier-Leporrier
AU - Marie-Pierre Galais
AU - Anne-Laure Bignon
AU - Aude Di Fiore
AU - Romain Desgrippes
AU - Laurent Miglianico
AU - Benoit Avisse
AU - Mathieu Baconnier
AU - You-Heng Lam
AU - Marie Dutherage
AU - David Sefrioui
AU - Karine Le Malicot
AU - Jean-Marc Phelip
AU - Pierre Michel
AU - André Gillibert
AU - Frédéric Di Fiore
PY - 2026
DA - 2026/09/08
JO - Digestive and Liver Disease
DO - 10.1016/j.dld.2024.05.014
UR - https://hal.science/hal-05742239v1
AB - PURPOSE: Relative dose intensity (RDI) is a measurement of chemotherapy (CT) dose defined as the actual dose received divided by the standard calculated dose during a set period. The study objective was to assess the impact of a RDI ≥ 80% on response and survival of patients treated in first line CT by FOLFOXIRI or FOLFIRINOX ± Bevacizumab (BV) for an unresectable metastatic colorectal cancer (mCRC). MATERIALS AND METHODS: It was a retrospective, non-interventional, multicenter study calculating RDI from the first cycles of CT to the first CT-scan evaluation (CT-scan1). Objective response and disease control rates (ORR and DCR), progression-free survival (PFS) and overall survival (OS) were compared between patients with RDI ≥ 80% and <80% and results were adjusted for age, gender, ECOG, tumor location, number of metastatic sites, RAS and BRAF status, the CT regimen, the use of BV, the delay from C1 to CT scan1. RESULTS: Among 152 screened patients, 100 met inclusion criteria, with a mean (± standard deviation) age at 59.0 (± 10.7) years. The ECOG performance status was 0-1 in 96 (96%) patients; metastases were synchronous in 95 (95%), RAS and BRAF were mutated in 60 (60%) and 22 (22%), respectively. ORR was observed in 51 (51%) at CT-scan1 with median PFS and OS of 10.5 and 21.9 months, respectively. A RDI ≥ 80% was observed in 44 (44%) patients without impact on ORR (ORa: 1.04, 95% CI: 0.37 to 2.89, p = 0.94) but was significantly associated to improved PFS and OS with HRa 0.50 (95%CI: 0.29 to 0.87, p = 0.013) and 0.52 (95% CI: 0.29 to 0.91, p = 0.023), respectively. CONCLUSION: Our results suggest a low level of FOLFOXIRI or FOLFIRINOX +/- BV exposure in first-line mCRC is associated with a significant trend on PFS and OS.
SN - 1590-8658
ER -